[Diagnosing Fauci’s Book](https://wbbsec.com/opinions-and-features/diagnosing-faucis-book-on-call-a-doctors-journey-in-public-service/)
[Diagnosing Fauci’s Book](https://wbbsec.com/opinions-and-features/diagnosing-faucis-book-on-call-a-doctors-journey-in-public-service/)
In: Press Releases

PDF:6.19.2013 Cempra Financial Advisor

WBB Securities Retained as Financial Advisor to Cempra, Inc.

Cempra closes $54.2 million financing to support its efforts to develop and commercialize novel antibiotic treatments

For Immediate Release
June 19, 2013

SAN DIEGO, CAWBB Securities acted as financial advisor to a transaction for Cempra, Inc. in an underwritten public offering that was announced today. The Company raised $54.2 million through the offering. Cempra intends to use funds raised to support its efforts to develop and commercialize Solithromycin for community acquired bacterial pneumonia and Taksta for use in chronic prosthetic joint infections.

About WBB Securities

WBB Securities is a leading investment management, investment banking, and equity research firm.  Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities.  WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.  The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche.  www.wbbsec.com

About Cempra, Inc.

Cempra Inc. is a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Two lead antibacterial products, both in the treatment of infectious diseases, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. Cempra is committed to developing commercially and medically differentiated products that provide a treatment alternative to address patient needs. The company is also utilizing its series of proprietary lead compounds from our novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.